EUROTARGET
European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity
| Coordinatore | STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.eurotargetproject.eu |
| Totale costo | 7˙818˙366 € |
| EC contributo | 5˙999˙550 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-03-01 - 2016-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | coordinator | 1˙792˙400.00 |
| 2 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 787˙550.00 |
| 3 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 550˙000.00 |
| 4 |
CESAR CENTRAL EUROPEAN SOCIETY FOR ANTICANCER DRUG RESEARCH EWIV
Organization address
address: HANGLUSSGASSE 4 1 3 contact info |
AT (WIEN) | participant | 521˙475.00 |
| 5 |
Pamgene International BV
Organization address
address: Nieuwstraat 30 contact info |
NL ('S-HERTOGENBOSCH) | participant | 471˙500.00 |
| 6 |
UNIVERSITAET DES SAARLANDES
Organization address
address: CAMPUS contact info |
DE (SAARBRUECKEN) | participant | 428˙128.50 |
| 7 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 373˙200.00 |
| 8 |
Cambridge University Hospitals NHS Foundation Trust
Organization address
address: Hills Rd contact info |
UK (Cambridge) | participant | 327˙648.00 |
| 9 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 258˙000.00 |
| 10 |
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Organization address
address: REGINA PACIS WEG 3 contact info |
DE (BONN) | participant | 163˙200.00 |
| 11 |
GRUPO ESPANOL DE TRATAMIENTO DE TUMORES UROLOGICOS ASOCIACION
Organization address
address: CALLE VELAZQUEZ 7 contact info |
ES (MADRID) | participant | 97˙125.00 |
| 12 |
Nome Ente NON disponibile
Organization address
city: Jena contact info |
DE (Jena) | participant | 82˙171.50 |
| 13 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 80˙000.00 |
| 14 |
UNIVERSITATEA DE MEDICINA SI FARMACIE'CAROL DAVILA' DIN BUCURESTI
Organization address
address: Dionisie Lupu 37 contact info |
RO (BUCHAREST) | participant | 48˙000.00 |
| 15 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 19˙152.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.'
Introduzione (Teaser)
Optimisation of a treatment regimen to target an individual condition is a desirable attribute that would maximise the chances of a patient successfully responding to therapy. European scientists set out to define new validated risk stratification criteria that could be used in personalised management of patients with metastatic renal cancer.